Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

MetAP2 inhibition increases energy expenditure through direct action on brown adipocytes.

Huang HJ, Holub C, Rolzin P, Bilakovics J, Fanjul A, Satomi Y, Plonowski A, Larson CJ, Farrell PJ.

J Biol Chem. 2019 Jun 14;294(24):9567-9575. doi: 10.1074/jbc.RA118.007302. Epub 2019 May 2.

PMID:
31048375
2.

CX3CL1-Fc treatment prevents atherosclerosis in Ldlr KO mice.

Riopel M, Vassallo M, Ehinger E, Pattison J, Bowden K, Winkels H, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Larson CJ, Ley K, Cabrales P, Witztum JL, Olefsky JM, Lee YS.

Mol Metab. 2019 Feb;20:89-101. doi: 10.1016/j.molmet.2018.11.011. Epub 2018 Dec 2.

3.

Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function.

Riopel M, Seo JB, Bandyopadhyay GK, Li P, Wollam J, Chung H, Jung SR, Murphy A, Wilson M, de Jong R, Patel S, Balakrishna D, Bilakovics J, Fanjul A, Plonowski A, Koh DS, Larson CJ, Olefsky JM, Lee YS.

J Clin Invest. 2018 Apr 2;128(4):1458-1470. doi: 10.1172/JCI94330. Epub 2018 Mar 5.

4.

Efficient high-throughput discovery of large peptidic hormones and biomarkers.

Taylor SW, Andon NL, Bilakovics JM, Lowe C, Hanley MR, Pittner R, Ghosh SS.

J Proteome Res. 2006 Jul;5(7):1776-84.

PMID:
16823986
5.

Mechanism of selective retinoid X receptor agonist-induced hypothyroidism in the rat.

Liu S, Ogilvie KM, Klausing K, Lawson MA, Jolley D, Li D, Bilakovics J, Pascual B, Hein N, Urcan M, Leibowitz MD.

Endocrinology. 2002 Aug;143(8):2880-5.

PMID:
12130551
6.

A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.

Etgen GJ, Oldham BA, Johnson WT, Broderick CL, Montrose CR, Brozinick JT, Misener EA, Bean JS, Bensch WR, Brooks DA, Shuker AJ, Rito CJ, McCarthy JR, Ardecky RJ, Tyhonas JS, Dana SL, Bilakovics JM, Paterniti JR Jr, Ogilvie KM, Liu S, Kauffman RF.

Diabetes. 2002 Apr;51(4):1083-7.

7.

Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.

Dana SL, Hoener PA, Bilakovics JM, Crombie DL, Ogilvie KM, Kauffman RF, Mukherjee R, Paterniti JR Jr.

Metabolism. 2001 Aug;50(8):963-71.

PMID:
11474486
8.

A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes.

Mukherjee R, Hoener PA, Jow L, Bilakovics J, Klausing K, Mais DE, Faulkner A, Croston GE, Paterniti JR Jr.

Mol Endocrinol. 2000 Sep;14(9):1425-33.

PMID:
10976920
9.
10.

Ablation of transplanted HTLV-I tax-transformed tumors in mice by antisense inhibition of NF-kappa B.

Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M.

Science. 1993 Mar 12;259(5101):1523. No abstract available.

PMID:
8456277
11.

Human T-cell leukemia virus type I tax transformation is associated with increased uptake of oligodeoxynucleotides in vitro and in vivo.

Kitajima I, Shinohara T, Minor T, Bibbs L, Bilakovics J, Nerenberg M.

J Biol Chem. 1992 Dec 25;267(36):25881-8.

12.

Ablation of transplanted HTLV-I Tax-transformed tumors in mice by antisense inhibition of NF-kappa B.

Kitajima I, Shinohara T, Bilakovics J, Brown DA, Xu X, Nerenberg M.

Science. 1992 Dec 11;258(5089):1792-5. Erratum in: Science. 1993 Mar 12;259(5101):1523.

PMID:
1299224

Supplemental Content

Loading ...
Support Center